Multigene genomic testing service to guide treatment selection for early-stage ER-positive, HER2-negative breast cancer

Summary

A.O.R.N. S.G. Moscati is procuring a service to perform multigene genomic tests to guide treatment selection for patients with early-stage ER-positive, HER2-negative breast cancer. The service is intended for the hospital’s oncology unit, and the estimated contract value is EUR 945,000.